Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Urogen Pharma (URGN) had Weighted-Average Shares Outstanding (Diluted) of 48.12M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$109.79M |
|
$-153.49M |
|
$12.45M |
|
$97.34M |
|
$234.65M |
|
$-124.86M |
|
$-28.55M |
|
$-153.42M |
|
$-153.42M |
|
$-153.49M |
|
$-153.49M |
|
$-153.49M |
|
$-153.49M |
|
$-124.86M |
|
$-126.43M |
|
48.12M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
48.12M |
$-3.19 |
|
$-3.19 |
|
| Balance Sheet Financials | |
$186.02M |
|
$0.64M |
|
$14.43M |
|
$200.46M |
|
$46.42M |
|
$122.21M |
|
$259.51M |
|
$305.93M |
|
$-105.47M |
|
$-105.47M |
|
$-105.47M |
|
48.35M |
|
| Cash Flow Statement Financials | |
$-162.44M |
|
$61.56M |
|
$39.92M |
|
$173.06M |
|
$112.09M |
|
$-60.97M |
|
$11.96M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.01 |
|
-- |
|
-- |
|
7.30 |
|
-1.16 |
|
88.66% |
|
-113.73% |
|
-113.73% |
|
-115.16% |
|
-139.74% |
|
-139.81% |
|
$-162.73M |
|
-- |
|
-- |
|
-- |
|
0.55 |
|
0.76 |
|
3.32 |
|
109.98 |
|
145.53% |
|
145.53% |
|
-76.57% |
|
-917.15% |
|
$-2.18 |
|
$-3.38 |
|
$-3.38 |
|